ArticleNature communications2022
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Genomic architecture of IRF4 rearrangements in childhood and adult large B-cell lymphomas.Blood advances · 2026Article
- Minimal disease detection by immunoglobulin high-throughput sequencing in pediatric Burkitt lymphoma.Blood advances · 2026Article
- Liquid biopsy for the diagnosis of EBV-positive Burkitt's lymphoma in endemic areas.Nature medicine · 2026Article
- miRNA profiling in pediatric and young adult Burkitt leukemia and lymphoma.Virchows Archiv : an international journal of pathology · 2026Article
- Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Feasibility of IG and TCR rearrangements quantification in ctDNA for monitoring clinical response in pediatric lymphomas.Frontiers in genetics · 2026Article
- Epstein-Barr virus infection shapes the genetic, transcriptomic, and immune microenvironment landscape of Burkitt lymphoma.Infectious agents and cancer · 2025Article
- Burkitt in disguise: clonal transformation of incidentally detected gallbladder diffuse large B-cell lymphoma in a liver transplant recipient.International journal of hematology · 2025Article
- Article
- Colorectal cancer-associated PCBP1 mutations disrupt protein stability in a dominant negative manner.bioRxiv : the preprint server for biology · 2025Article
- Audit of B-cell cancer genes.Blood advances · 2025Review
- Subtyping Burkitt Lymphoma by DNA Methylation.Genes, chromosomes & cancer · 2025Article
- Article
- Pan-cancer analysis reveals age-associated genetic alterations in protein domains.American journal of human genetics · 2025Article
- Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance.Leukemia · 2025Article
- MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma.Blood cancer journal · 2024Article
- Article
- Discovery of first-in-class PROTACs targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of Burkitt lymphoma.RSC medicinal chemistry · 2024Article
- Genetic alterations in mature B- and T-cell lymphomas - a practical guide to WHO-HAEM5.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2024Article
- Challenging our understanding of B-cell lymphomagenesis and risk: Paediatric high-grade B-cell lymphoma, not otherwise specified with a DDX3X::MLLT10 fusion and an IGH deletion.Pediatric blood & cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While survival has improved for Burkitt lymphoma patients, potential differences in outcome between pediatric and adult patients remain unclear. In both age groups, survival remains poor at relapse. Therefore, we conducted a comparative study in a large pediatric cohort, including 191 cases and 97 samples from adults. While TP53 and CCND3 mutation frequencies are not age related, samples from pediatric patients showed a higher frequency of mutations in ID3, DDX3X, ARID1A and SMARCA4, while several genes such as BCL2 and YY1AP1 are almost exclusively mutated in adult patients. An unbiased analysis reveals a transition of the mutational profile between 25 and 40 years of age. Survival analysis in the pediatric cohort confirms that TP53 mutations are significantly associated with higher incidence of relapse (25 ± 4% versus 6 ± 2%, p-value 0.0002). This identifies a promising molecular marker for relapse incidence in pediatric BL which will be used in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.